Survodutide or Mazdutide: A Designed Ratio Against an Inherited One

The same receptor pair, the GLP-1 receptor and the glucagon receptor, is addressed by survodutide and by mazdutide, yet the two were built from quite different origins. One of them, survodutide (development code BI 456906), is an acylated scaffold engineered from the ground up so that its potency across the two targets lands on a predetermined ratio. The other, mazdutide (also cited as IBI362 or LY3305677), is a durability-enhanced form of the naturally dual-acting proglucagon product oxyntomodulin. Setting survodutide beside mazdutide thus raises no question about receptor identity, only about proportion, and about whether a deliberately specified balance performs unlike the one that arose naturally.

Each is stocked here as sealed lyophilized powder at three fill weights — 5, 10 and 20 mg — every vial accompanied by its own HPLC certificate; look for survodutide and mazdutide under GLP-1 and incretin peptides. Neither is a medicine: both are research chemicals meant for in-vitro and preclinical laboratory use.

The rationale for a glucagon arm

Incretin analogues acting alone work along a single axis, with GLP-1 receptor engagement associated in the literature with lower food intake, delayed gastric emptying and glucose-dependent insulin release. Introducing glucagon receptor activity opens a second and markedly different set of endpoints: hepatic substrate handling, ketogenesis, mobilisation of lipid and, in rodent indirect calorimetry, raised energy expenditure. For both molecules the reported design reasoning is that the incretin arm delivers intake suppression while the glucagon arm delivers the expenditure and hepatic elements, with the incretin arm simultaneously counterbalancing the glycaemic consequences of glucagon receptor stimulation.

So much they share. Where they diverge is in how each balance was reached. Survodutide is a purpose-built dual agonist whose sequence was optimised to land on a target potency ratio, making that ratio an intentional parameter. Mazdutide retains the oxyntomodulin template, so its ratio is inherited rather than selected and the molecule is altered only enough to survive in circulation. For a laboratory assembling a structure-activity series, that contrast is the experiment.

Structure and stabilisation

Oxyntomodulin in its native form is a 37-residue proglucagon product that activates both receptors yet disappears within minutes, largely via dipeptidyl peptidase-4 cleavage and renal filtration. Mazdutide adds substitutions that blunt that cleavage plus a fatty-acid side chain permitting reversible albumin binding, the same lipidation approach used across the modern incretin class. Survodutide applies that same broad tactic, acylation for albumin association, to a sequence that copies no single native hormone directly.

At the bench, the acyl chain counts for more than the sequence difference does. Both peptides are amphipathic with a lipophilic tail, so in dilute aqueous solution both act like near-surfactants, and adsorption onto glass and polypropylene at low concentration is the commonest cause of unexplained potency loss in cell assays with either. Do not assume one compound's stock-preparation protocol transfers to the other without checking concentration.

The evidence base for each

Published human evidence for both belongs to their sponsors' investigational clinical programmes, regulated activities using pharmaceutical-grade drug product under medical supervision. None of that transfers to research-grade material purchased as a reagent, and nothing here should be read as implying otherwise.

What actually concerns a reagent user is the preclinical and in-vitro layer. For both compounds that generally means cyclic-AMP accumulation assays in cells transfected separately with human GCGR and human GLP-1R to fix the potency ratio; beta-arrestin recruitment assays, an area where the incretin field reports meaningful differences in bias between analogues; hepatocyte and adipocyte systems, where glucagon-driven readouts such as glucose output, ketone production and lipid content can be isolated from anything intake-related; and rodent energy-balance studies combining food intake measurements with indirect calorimetry. Survodutide has also featured in preclinical work aimed at hepatic endpoints, in keeping with its glucagon emphasis, while mazdutide appears in work framed specifically around the oxyntomodulin lineage.

Matching compound to question

Survodutide when the glucagon arm is the variable

Where the design asks how far the glucagon contribution can be pushed before glycaemic or hepatic readouts reverse, survodutide is the more informative probe, since its glucagon arm is the feature it was engineered around. It is also the obvious comparator when a triple agonist such as retatrutide is under investigation and the question is what GIP adds on top of an existing GLP-1 plus glucagon baseline, because survodutide isolates that baseline.

Mazdutide when the native template is the point

Where the hypothesis concerns oxyntomodulin biology, whether the endogenous receptor ratio is functionally distinctive or whether a stabilised native peptide reproduces what designed scaffolds achieve, mazdutide is the right tool because it keeps that template intact. It is also the better reference for a laboratory characterising its own oxyntomodulin-derived constructs and needing a well-defined comparator from the same structural family.

Both when the ratio itself is the question

In practice the commonest design employs both. Two dual agonists sharing a receptor pair but differing in balance give a two-point series, and adding a pure GLP-1 agonist such as semaglutide as the zero-glucagon anchor makes three. That layout allows a group to attribute an effect to glucagon receptor engagement rather than to the incretin component, which no single-compound experiment can achieve. Matching 5, 10 and 20 mg sizes for both make molar-matched parallel preparation straightforward.

Handling, reconstitution and storage

They behave alike enough that one laboratory protocol normally serves both, subject to the caveats below. Keep sealed lyophilized vials frozen for long-term storage and let them warm to room temperature before opening so atmospheric moisture cannot condense onto cold powder. Reconstitute by directing the diluent down the vial wall rather than straight onto the cake, then leave the vial to dissolve without shaking, since agitation causes foaming and interfacial denaturation in acylated peptides.

Concentration is a laboratory calculation rather than a usage recommendation: reconstituting a 10 mg vial in 2 mL of diluent gives 5 mg/mL, so 0.1 mL of that solution holds 500 mcg of peptide. The arithmetic is identical for both compounds, but in each case the labelled vial mass includes counter-ion and residual water, so net peptide falls short of what the label implies, and the shortfall need not be the same for two different molecules. Groups comparing them quantitatively should anchor to a measured concentration instead of the label. Our reconstitution guide and storage guide give the full procedure, and preparing single-use aliquots keeps either stock from repeated freezing and thawing.

Purity, identity and certificate checks

Ask for the lot-matched certificate with each vial and check three things: an HPLC purity figure accompanied by a visible chromatogram rather than a bare number, a mass spectrometry result consistent with the expected mass of the acylated peptide, and a lot number matching the vial you are holding. With acylated dual agonists the most telling impurity signals are late-eluting peaks, which may indicate acylation by-products that were not fully removed, and any sign of des-acyl species, which keep the sequence but lose the albumin binding that defines the molecule's exposure profile. Our guide to reading a COA explains what each section of the document should contain.

Regulatory framing

Investigational status applies to each of them. No authorisation as a medicine exists in the EU or the United States, and material from us carries a laboratory-use-only label. Whatever clinical figures have been reported come from sponsor-run trials conducted with pharmaceutical product under supervision, cited here only to sketch the state of the published record. Our weight-management research overview places these molecules in their wider metabolic context.